Skip to main content
Premium Trial:

Request an Annual Quote

FDA Approves Foundation Medicine Test as CDx With Roche's Rozlytrek

NEW YORK – Roche subsidiary Foundation Medicine announced on Thursday that its FoundationOne CDx test has been approved by the US Food and Drug Administration as a companion diagnostic with Roche's Rozlytrek (entrectinib). 

The test was approved by the FDA to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumors for whom treatment with Rozlytrek could be appropriate. It is the first and only FDA-approved CDx for this indication, Roche said in a statement. As a condition of the test's approval, Foundation will conduct a study to further demonstrate FoundationOne CDx's ability to identify patients with ROS1 fusion-mutated NSCLC who could potentially benefit from Rozlytrek.

Rozlytrek is a targeted therapy approved to treat ROS1 fusion-positive metastatic NSCLC and a tumor-agnostic medicine for locally advanced or solid tumors that have NTRK fusions. In 2019, the FDA granted accelerated approval to the drug as a treatment for adult and adolescent patients whose cancers have NTRK gene fusions and are out of treatment options, as well as for adults with metastatic non-small cell lung cancer whose tumors are ROS1-positive.

"The ability to tailor cancer therapies based on specific genomic alterations using validated comprehensive genomic profiling (CGP) has transformed the traditional 'one-size fits-all' approach to cancer," Levi Garraway, Roche's chief medical officer and head of global product development, said in a statement. "This approval marks a significant step forward in expanding treatment options and improving outcomes for patients, particularly those with rare tumors."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.